SEC Filings

Form 10-Q
OVID THERAPEUTICS INC. filed this Form 10-Q on 11/08/2018
Document Outline
Entire Document (3559.9 KB)
Subdocument 1 - 10-Q - 10-Q 9/30/18
Page 1 - UNITED STATES
Page 2 - Table of Contents
Page 3 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - OVID THERAPEUTICS INC.
Page 6 - OVID THERAPEUTICS INC.
Page 7 - OVID THERAPEUTICS INC.
Page 8 - OVID THERAPEUTICS INC.
Page 9 - E) Recent Accounting Pronouncements
Page 10 - New accounting standards which have not yet been adopted
Page 11 - NOTE 3 PRECLINICAL AND CLINICAL AGREEMENTS
Page 12 - NOTE 4 CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS
Page 13 - NOTE 6 ACCRUED EXPENSES
Page 14 - N/A
Page 15 - NOTE 9 INCOME TAXES
Page 16 - NOTE 10 COMMITMENTS AND CONTINGENCIES
Page 17 - Severance Benefits
Page 18 - NOTE 12 NET LOSS PER SHARE
Page 19 - Item 2.Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 20 - Clinical Developments
Page 21 - Research and Development Expenses
Page 22 - Interest Income
Page 23 - General and Administrative Expenses
Page 24 - General and Administrative Expenses
Page 25 - Cash Flows
Page 26 - Emerging Growth Company Status
Page 27 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 28 - PART II OTHER INFORMATION
Page 29 - We have a limited operating history and have never generated any revenue from drug sales. Our limite
Page 30 - We will require additional capital to finance our operations, which may not be available on acceptab
Page 31 - We may be required to make significant payments in connection with our licenses of OV101 from Lundbe
Page 32 - Risks Related to the Development and Commercialization of Our Drug Candidates
Page 33 - We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and
Page 34 - Angelman syndrome has no FDA-approved treatments, and the clinical endpoints to obtain approval are
Page 35 - We may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candid
Page 36 - We are heavily dependent on our relationship with Takeda for the development and commercialization o
Page 37 - Our drug candidates may cause undesirable side effects or have other properties that could delay or
Page 38 - We may be required to relinquish important rights to and control over the development and commercial
Page 39 - Even if our current or future drug candidates receive marketing approval, they may fail to achieve m
Page 40 - Even if we obtain regulatory approval for our current or future drug candidates, they will remain su
Page 41 - Even if we obtain and maintain approval for our current or future drug candidates from the FDA, we m
Page 42 - Product liability lawsuits against us could cause us to incur substantial liabilities and could limi
Page 43 - N/A
Page 44 - Coverage and adequate reimbursement may not be available for our current or any future drug candidat
Page 45 - Risks Related to Our Intellectual Property
Page 46 - N/A
Page 47 - We may be unable to prevent third parties from selling, making, promoting, manufacturing, or distrib
Page 48 - Third parties may claim that we are infringing their intellectual property rights, or otherwise alle
Page 49 - We may be subject to claims asserting that our employees, consultants or advisors have wrongfully us
Page 50 - Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the
Page 51 - We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and cli
Page 52 - Risks Related to Our Business Operations, Employee Matters and Managing Growth
Page 53 - Our employees, principal investigators, consultants and commercial partners may engage in misconduct
Page 54 - Risks Related to the Ownership of Our Common Stock
Page 55 - We may sell additional equity or debt securities or enter into other arrangements to fund our operat
Page 56 - If we engage in future acquisitions or strategic partnerships, this may increase our capital require
Page 57 - We will continue to incur increased costs as a result of operating as a public company, and our mana
Page 58 - We may be subject to securities litigation, which is expensive and could divert management attention
Page 59 - Some provisions of our charter documents and Delaware law may have anti-takeover effects that could
Page 60 - Item 6. Exhibits.
Page 61 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer